High-yield points
- Get a molecular diagnosis on every spinal ependymoma. MYCN amplification marks a disseminating, early-relapsing tumor, often intradural extramedullary .
- Pediatric myxopapillary ependymoma is grade 2 and seeds the neuraxis. Up to half are disseminated at diagnosis, so image the whole neuraxis .
- Remove an MPE en bloc with the capsule intact: that gave no recurrences, against 15% after capsular violation .
- Intramedullary SP-EPN: a central tumor with a cap sign or syrinx usually has a plane. Extent of resection drives PFS .
- NF2: watch asymptomatic cervical ependymomas, and operate for symptoms .
- Children nearly always survive. Measure success by function, continence and spinal alignment as well as by PFS .
Spinal ependymomas are uncommon before adolescence. In children they behave differently from adult spinal ependymomas .
- Three molecular types matter :
- myxopapillary ependymoma (SP-MPE): the commonest in children;
- classic spinal ependymoma (SP-EPN);
- MYCN-amplified spinal ependymoma (SP-EPN-MYCN): rare and aggressive.
- Children almost always survive, but progression is common .
- Pediatric myxopapillary tumors disseminate along the neuraxis far more often than adult ones. Image the whole neuraxis at diagnosis and in follow-up .
- Surgery: aim for en bloc removal of an MPE and gross-total removal of an intramedullary SP-EPN. Test every tumor for MYCN amplification .
Classification (WHO 2021 and methylation)
- Ependymomas group by compartment.
- Methylation profiling of 500 ependymal tumors defined nine molecular subgroups, three in each compartment: spine, posterior fossa and supratentorial .
- This predicts outcome better than histological grade .
- WHO 2021 spinal types :
- Spinal ependymoma: characteristic alteration NF2.
- Spinal ependymoma, MYCN-amplified.
- Myxopapillary ependymoma: now CNS WHO grade 2.
- Subependymoma.
- The modifier "anaplastic" is no longer routinely used.
- German HIT-MED registry (83 patients aged ≤22; 47 methylation-profiled) :
- Molecular types: SP-MPE 63%, SP-EPN 33%, SP-EPN-MYCN 4%.
- NF2-related schwannomatosis: 10 patients.
- Reclassified: one tumor turned out to be an anaplastic pilocytic astrocytoma, which is why profiling is worth doing.
The aggressive one: SP-EPN-MYCN
- First series (13 tumors), from methylation profiling and confirmed by FISH :
- Site: mostly intradural extramedullary in the thoracic and cervical spine, with infiltration of the cord;
- Spread: dissemination in 100%, with diffuse leptomeningeal spread through the whole CNS;
- Outcome: median PFS 17 months and median OS 87 months, similar to ST-EPN-RELA and PF-EPN-A.
- Further reports:
- Mayo series: 4 adolescent and young adult women, all grade 3 histology, and aggressive behavior ;
- NIH series: grade 3 features with no NF2 alteration and a distinct methylation cluster. This brought the published total to 27 cases .
- In children: both HIT-MED MYCN cases relapsed within 2.3 years, and one died .
- Practical point: an ependymoma in the thoracic intradural extramedullary space, or with leptomeningeal coating, should prompt MYCN testing and staging of the whole neuraxis .
Myxopapillary ependymoma in children
- Where: the conus medullaris and filum terminale .
- How it presents: pain, scoliosis and urinary symptoms .
- Dissemination is common:
- Boston (18 children, median age 14): 50% had leptomeningeal seeding at presentation, most often in the distal thecal sac .
- Utah plus literature (26 children): 35% had CNS metastases, rising to 58% (7/12) when the neuraxis was actually screened .
- Late drop metastases occurred after GTR, at a mean of about 44 months, almost all to the sacral sac and one to the brain .
- Survival is excellent; event-free survival is not:
- Boston: 10-year OS 100%, but 10-year EFS only 26%. Disseminated disease trended worse: 13% vs. 57% EFS .
- SEER (122 patients ≤21): 5- and 10-year OS of 97% and 95%. GTR alone beat subtotal resection plus radiotherapy .
- The capsule matters (mixed-age series of 58) :
- Recurrence by extent of resection:
- en bloc, capsule intact: 0%;
- GTR with capsular violation: 15%;
- subtotal resection: 45%.
- Capsular violation predicted recurrence.
- Adjuvant radiotherapy after violation: a nonsignificant trend to longer 5-year PFS, 83% vs. 50%.
Intramedullary spinal ependymoma (SP-EPN)
- Imaging: compared with astrocytoma, ependymoma favors :
- central location;
- diffuse enhancement;
- hemorrhage and a hemosiderin cap sign;
- syringohydromyelia, the only independent predictor (OR 62.9).
- Surgical meaning: these features suggest a resectable plane.
- Surgery:
- Approach: dorsal midline myelotomy.
- Neuromonitoring: muscle MEPs, SSEPs and the D-wave. A D-wave fall of more than 50% was the main indication to stop in Sala's series .
- Extent of resection: together with WHO grade, it significantly predicted PFS in pediatric spinal ependymoma .
- Outcomes in HIT-MED :
- Overall survival: 5-year 100%, 10-year 86%;
- PFS: 5-year 65%, 10-year 54%;
- 5-year PFS by type: SP-MPE 65% vs. SP-EPN 78%, not significantly different;
- MPE subtypes: subtype B trended better than subtype A, 86% vs. 56%.
- Population data: in the NCDB (ages 0–21), ependymoma was the commonest intramedullary tumor, at 57.5%. Astrocytoma carried worse survival .
NF2-related schwannomatosis
- NF2 is the defining alteration of spinal ependymoma in WHO 2021 .
- Massachusetts General series of 55 NF2 patients :
- Number: ependymomas were multiple in 58%.
- Site: mostly cervical or cervicomedullary, in 86% of imaging studies.
- Symptoms: 76% were asymptomatic.
- Surgery: needed in only 20% over a median of 50 months.
- Recommended approach: surveillance for asymptomatic tumors, even cystic ones that expand the cord.
- Bevacizumab: all 8 treated patients with symptomatic NF2 ependymomas improved clinically, but only 5 had a radiographic response .
Follow-up and late effects
- MRI of the whole neuraxis:
- When: at diagnosis and during surveillance, especially for MPE and MYCN-amplified tumors ;
- How long: relapses come late, up to years after GTR .
- Spinal deformity:
- Incidence: progressive deformity needing fusion followed 27% of pediatric intramedullary resections .
- Highest risk: age under 13, preoperative scoliosis, the thoracolumbar junction, a syrinx and repeat surgery.
- Laminoplasty: reduced later fusion in one pediatric cohort, 5% vs. 30% .
Related topics
- Ependymoma in Children: intracranial ependymoma and the WHO molecular groups.
- Spinal Cord Gliomas: intramedullary astrocytoma versus ependymoma.
- Neurofibromatosis: NF2-related schwannomatosis.
- Intraoperative Neuromonitoring Under Anesthesia: D-wave, MEP and SSEP monitoring during resection.
- Syringomyelia and Hydromyelia in Children: syrinx types, causes and management.
References
- Pajtler KW, Witt H, Sill M, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 2015;27(5):728–743. doi:10.1016/j.ccell.2015.04.002. PMID 25965575. verified
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
- Engertsberger L, Benesch M, Mynarek M, et al. Impact of molecular classification on prognosis in children and adolescents with spinal ependymoma: results from the HIT-MED database. Neurooncol Adv 2024;6(1):vdae179. doi:10.1093/noajnl/vdae179. PMID 39713042. verified
- Ghasemi DR, Sill M, Okonechnikov K, et al. MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathol 2019;138(6):1075–1089. doi:10.1007/s00401-019-02056-2. PMID 31414211. verified
- Swanson AA, Raghunathan A, Jenkins RB, et al. Spinal cord ependymomas with MYCN amplification show aggressive clinical behavior. J Neuropathol Exp Neurol 2019;78(9):791–797. doi:10.1093/jnen/nlz064. PMID 31373367. verified
- Raffeld M, Abdullaev Z, Pack SD, et al. High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. Acta Neuropathol Commun 2020;8(1):101. doi:10.1186/s40478-020-00973-y. PMID 32641156. verified
- Bandopadhayay P, Silvera VM, Ciarlini PDSC, et al. Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol 2016;126(1):165–174. doi:10.1007/s11060-015-1955-2. PMID 26468139. verified
- Fassett DR, Pingree J, Kestle JR. The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg 2005;102(1 Suppl):59–64. doi:10.3171/ped.2005.102.1.0059. PMID 16206735. verified
- Lucchesi KM, Grant R, Kahle KT, et al. Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database. J Neurooncol 2016;130(1):133–140. doi:10.1007/s11060-016-2218-6. PMID 27423644. verified
- Abdallah A, Emel E, Gündüz HB, et al. Long-term surgical resection outcomes of pediatric myxopapillary ependymoma: experience of two centers and brief literature review. World Neurosurg 2020;136:e245–e261. doi:10.1016/j.wneu.2019.12.128. PMID 31899399. verified
- Abdulaziz M, Mallory GW, Bydon M, et al. Outcomes following myxopapillary ependymoma resection: the importance of capsule integrity. Neurosurg Focus 2015;39(2):E8. doi:10.3171/2015.5.FOCUS15164. PMID 26235025. verified
- Plotkin SR, O'Donnell CC, Curry WT, et al. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. J Neurosurg Spine 2011;14(4):543–547. doi:10.3171/2010.11.SPINE10350. PMID 21294614. verified
- Farschtschi S, Merker VL, Wolf D, et al. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand 2016;133(6):475–480. doi:10.1111/ane.12490. PMID 26369495. verified
- Kim DH, Kim JH, Choi SH, et al. Differentiation between intramedullary spinal ependymoma and astrocytoma: comparative MRI analysis. Clin Radiol 2014;69(1):29–35. doi:10.1016/j.crad.2013.07.017. PMID 24034546. verified
- Jagtiani P, Karabacak M, Bahadir Z, et al. Pediatric intramedullary spinal cord tumors: a national cancer database analysis of demographics, patterns of care, and survival. Clin Neurol Neurosurg 2024;244:108457. doi:10.1016/j.clineuro.2024.108457. PMID 39042966. verified
- Sala F, Palandri G, Basso E, et al. Motor evoked potential monitoring improves outcome after surgery for intramedullary spinal cord tumors: a historical control study. Neurosurgery 2006;58(6):1129–1143. doi:10.1227/01.NEU.0000215948.97195.58. PMID 16723892. verified
- Yao KC, McGirt MJ, Chaichana KL, et al. Risk factors for progressive spinal deformity following resection of intramedullary spinal cord tumors in children: an analysis of 161 consecutive cases. J Neurosurg 2007;107(6 Suppl):463–468. doi:10.3171/PED-07/12/463. PMID 18154014. verified
- McGirt MJ, Chaichana KL, Atiba A, et al. Incidence of spinal deformity after resection of intramedullary spinal cord tumors in children who underwent laminectomy compared with laminoplasty. J Neurosurg Pediatr 2008;1(1):57–62. doi:10.3171/PED-08/01/057. PMID 18352804. verified
Verification (2026-11-16):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed.
- Every number was checked against the PubMed abstract.
- The WHO 2021 details were confirmed in the open-access full text of reference 2 (PMC8328013):
- the four spinal ependymal types (Table 1);
- "Spinal ependymomas: NF2, MYCN" (Table 2);
- myxopapillary ependymoma as grade 2 (Table 3);
- the dropped "anaplastic" modifier.
Caveats:
- The SP-MPE, SP-EPN and SP-SE subgroup names, and the conus and filum origin of MPE, are standard nomenclature and anatomy, not quoted from the cited abstracts.
- The advice to test for MYCN is the recommendation of reference 4.
- Reference 11 is a mixed-age series with a mean age of 41.
- References 7, 8 and 10 are small.
- The figure is an original schematic.